Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.…
Mandatory notification of transaction - merger of Obligasjon 2 AS into Kvantia AS
Gentian Diagnostics (OSL: GENT) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 63 employees.
The shares were at 39.60 NOK on 20 November 2026, down 29.3% over 52 weeks. Its 52-week range is 33.50 NOK to 60.00 NOK: the price is 34.0% below the high and 18.2% above the low.
Its market capitalisation is 612.16M NOK. It pays a dividend yielding 1.52% (it pays out 47% of its earnings), against a median of 2.35% among the dividend payers in that peer group.
Gentian Diagnostics reports return on equity of 6.5%, an operating margin of 14.7% and revenue up 22.1% year over year.
It holds more cash than debt, a net cash position of 75.46M NOK. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 60.00 NOK is 51.5% above the current price.